KYMR logo

Kymera Therapeutics, Inc. (KYMR) Cash From Financing

Annual CFF:

$608.85M+$604.66M(+14424.12%)
December 31, 2024

Summary

  • As of today, KYMR annual cash from financing is $608.85 million, with the most recent change of +$604.66 million (+14424.12%) on December 31, 2024.
  • During the last 3 years, KYMR annual cash from financing has risen by +$358.57 million (+143.27%).
  • KYMR annual cash from financing is now at all-time high.

Performance

KYMR Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherKYMRcash flow metrics

Quarterly CFF:

$39.51M-$206.22M(-83.92%)
September 30, 2025

Summary

  • As of today, KYMR quarterly cash from financing is $39.51 million, with the most recent change of -$206.22 million (-83.92%) on September 30, 2025.
  • Over the past year, KYMR quarterly cash from financing has dropped by -$211.41 million (-84.25%).
  • KYMR quarterly cash from financing is now -88.83% below its all-time high of $353.76 million, reached on March 31, 2024.

Performance

KYMR Quarterly Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherKYMRcash flow metrics

TTM CFF:

$288.26M-$211.41M(-42.31%)
September 30, 2025

Summary

  • As of today, KYMR TTM cash from financing is $288.26 million, with the most recent change of -$211.41 million (-42.31%) on September 30, 2025.
  • Over the past year, KYMR TTM cash from financing has dropped by -$319.76 million (-52.59%).
  • KYMR TTM cash from financing is now -52.66% below its all-time high of $608.85 million, reached on December 31, 2024.

Performance

KYMR TTM Cash From Financing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherKYMRcash flow metrics

Cash From Financing Formula

CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities

KYMR Cash From Financing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+10000.0%-84.3%-52.6%
3Y3 Years+143.3%-73.8%+88.3%
5Y5 Years+1644.0%-79.9%-7.0%

KYMR Cash From Financing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Yearat high>+9999.0%-88.8%>+9999.0%-52.7%+6776.4%
5Y5-Yearat high>+9999.0%-88.8%>+9999.0%-52.7%+6776.4%
All-TimeAll-Timeat high>+9999.0%-88.8%+9904.0%-52.7%+6776.4%

KYMR Cash From Financing History

DateAnnualQuarterlyTTM
Sep 2025
-
$39.51M(-83.9%)
$288.26M(-42.3%)
Jun 2025
-
$245.73M(>+9900.0%)
$499.67M(+95.7%)
Mar 2025
-
$258.00K(-90.7%)
$255.35M(-58.1%)
Dec 2024
$608.85M(>+9900.0%)
$2.77M(-98.9%)
$608.85M(+0.1%)
Sep 2024
-
$250.92M(>+9900.0%)
$608.02M(+70.4%)
Jun 2024
-
$1.41M(-99.6%)
$356.90M(+0.0%)
Mar 2024
-
$353.76M(>+9900.0%)
$356.79M(+8411.2%)
Dec 2023
$4.19M(-97.3%)
$1.93M(+1038.8%)
$4.19M(-0.5%)
Sep 2023
-
-$206.00K(-115.8%)
$4.21M(-97.3%)
Jun 2023
-
$1.30M(+12.6%)
$154.91M(+0.6%)
Mar 2023
-
$1.16M(-40.7%)
$153.97M(+0.6%)
Dec 2022
$153.00M
$1.95M(-98.7%)
$153.00M(-0.1%)
DateAnnualQuarterlyTTM
Sep 2022
-
$150.50M(>+9900.0%)
$153.10M(-38.4%)
Jun 2022
-
$364.00K(+96.8%)
$248.64M(-0.5%)
Mar 2022
-
$185.00K(-91.0%)
$249.87M(-0.2%)
Dec 2021
$250.28M(-13.5%)
$2.05M(-99.2%)
$250.28M(+0.7%)
Sep 2021
-
$246.04M(>+9900.0%)
$248.50M(+25.0%)
Jun 2021
-
$1.59M(+167.6%)
$198.73M(+1.0%)
Mar 2021
-
$595.00K(+120.4%)
$196.74M(-32.0%)
Dec 2020
$289.26M(+728.6%)
$270.00K(-99.9%)
$289.26M(-6.7%)
Sep 2020
-
$196.28M(>+9900.0%)
$310.08M(+172.5%)
Jun 2020
-
-$403.00K(-100.4%)
$113.81M(-0.4%)
Mar 2020
-
$93.12M(+341.5%)
$114.21M(+441.5%)
Dec 2019
$34.91M(-34.0%)
$21.09M
$21.09M
Dec 2018
$52.93M
-
-

FAQ

  • What is Kymera Therapeutics, Inc. annual cash from financing?
  • What is the all-time high annual cash from financing for Kymera Therapeutics, Inc.?
  • What is Kymera Therapeutics, Inc. annual cash from financing year-on-year change?
  • What is Kymera Therapeutics, Inc. quarterly cash from financing?
  • What is the all-time high quarterly cash from financing for Kymera Therapeutics, Inc.?
  • What is Kymera Therapeutics, Inc. quarterly cash from financing year-on-year change?
  • What is Kymera Therapeutics, Inc. TTM cash from financing?
  • What is the all-time high TTM cash from financing for Kymera Therapeutics, Inc.?
  • What is Kymera Therapeutics, Inc. TTM cash from financing year-on-year change?

What is Kymera Therapeutics, Inc. annual cash from financing?

The current annual cash from financing of KYMR is $608.85M

What is the all-time high annual cash from financing for Kymera Therapeutics, Inc.?

Kymera Therapeutics, Inc. all-time high annual cash from financing is $608.85M

What is Kymera Therapeutics, Inc. annual cash from financing year-on-year change?

Over the past year, KYMR annual cash from financing has changed by +$604.66M (+14424.12%)

What is Kymera Therapeutics, Inc. quarterly cash from financing?

The current quarterly cash from financing of KYMR is $39.51M

What is the all-time high quarterly cash from financing for Kymera Therapeutics, Inc.?

Kymera Therapeutics, Inc. all-time high quarterly cash from financing is $353.76M

What is Kymera Therapeutics, Inc. quarterly cash from financing year-on-year change?

Over the past year, KYMR quarterly cash from financing has changed by -$211.41M (-84.25%)

What is Kymera Therapeutics, Inc. TTM cash from financing?

The current TTM cash from financing of KYMR is $288.26M

What is the all-time high TTM cash from financing for Kymera Therapeutics, Inc.?

Kymera Therapeutics, Inc. all-time high TTM cash from financing is $608.85M

What is Kymera Therapeutics, Inc. TTM cash from financing year-on-year change?

Over the past year, KYMR TTM cash from financing has changed by -$319.76M (-52.59%)
On this page